Overactive bladder (OAB) is associated with considerable clinical and economic burden. Treatment of patients with OAB using anticholinergics is limited by tolerability issues and increased anticholinergic burden, which is associated with increased risk of dementia and falls/fractures.

Biographies:

Jeff Nesheim, PharmD, MS, Director Medical Science Liaison, Payor, Urovant Sciences, Inc., Irvine, CA